Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
about
Targeted therapies in sarcomas: challenging the challengeThe neurotransmitter dopamine modulates vascular permeability in the endotheliumWhy are tumour blood vessels abnormal and why is it important to know?New chemotherapy strategies and biological agents in the treatment of childhood ependymomaModulation of Host Angiogenesis as a Microbial Survival Strategy and Therapeutic TargetTargeting hypoxic response for cancer therapyCancer stem cells and immunoresistance: clinical implications and solutionsEvading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumorsProfile of bevacizumab and its potential in the treatment of cervical cancerRho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunitiesThe cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysisOptimal combination of antiangiogenic therapy for hepatocellular carcinomaA paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapyExploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunitiesLung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionTips, stalks, tubes: notch-mediated cell fate determination and mechanisms of tubulogenesis during angiogenesisHypertension in patients with cancerCombination therapy for renal cell cancer: what are possible options?Contemporary use of bevacizumab in ovarian cancerSmall molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathwaysr84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity inductionGastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation TherapyA novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNAAngiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysisProdrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor SunitinibPhase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancerSmall-Molecule Procaspase-3 Activation Sensitizes Cancer to Treatment with Diverse ChemotherapeuticsTargeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyMolecular mechanisms and clinical applications of angiogenesisTumor angiogenesisHigh-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation.Stimulus-responsive ultrasound contrast agents for clinical imaging: motivations, demonstrations, and future directions.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.More sound cancer therapy biomarker development with active noise control.Angiogenic inhibition in high-grade gliomas: past, present and future.Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.Normalization of the vasculature for treatment of cancer and other diseases.AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels.Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.
P2860
Q21285014-53186F27-3B0A-426D-A985-43F0B8D7BE65Q24317718-BA184E04-F21A-4A68-93BC-DB93CD61A495Q24652018-BF68D49D-CAE8-48A8-9EE0-863594999AAAQ24658324-4D076E1B-EA9D-40B8-8FBA-2183898AECA3Q26748251-0DFCBC41-DCBA-4EB2-8918-B0D92BB5DF8AQ26767351-4F3B8794-3774-4F2A-9DEE-AD8CAA84436DQ26769757-04EF7A94-9E86-46D0-B9ED-E413BFC2304EQ26773795-717156BF-7EDA-4A2B-9908-962920212C6AQ26774168-26E78660-06CB-450C-B2BB-2A86978E68AFQ26778344-C9D2C010-753C-4455-89DC-5294BB3021E0Q26796921-A6A5DA36-AEF5-4B35-99D7-EC12250A1599Q26799458-D3C03503-7DD7-4BBC-AD6A-8A512048345CQ26824462-FB3C1CCE-E355-49E5-B423-A334DFDB628CQ26828930-F3305D7A-8523-4DFD-8666-D218BB63B209Q26850218-B91A50BB-151F-42AF-8D94-37756C5884BDQ26863766-21A3009A-FA50-4C07-899B-B45C592246A6Q27003980-D2542324-2AA8-4102-9018-2F4F6C208609Q27011663-CD18EA82-B20A-412D-9E82-FC614FFBC36BQ27023510-91A90174-A303-495E-930B-3646DAFB1CDDQ27317155-B08669B0-FF00-4D35-9DCC-9671E193AB9DQ27321768-98259003-6EF9-47EC-9D2B-3ABA0FEBF1B2Q28086904-4C015072-A70F-424B-A766-00A1B30D90B5Q28472818-CCE273EF-3C46-4F78-935B-035BFE73C8D5Q28534015-7CEA74B6-21EF-425B-B6D3-621A6D4151E8Q28550556-D857623B-9EA6-4C12-9157-834B04EA4BA3Q28728593-F68F622F-5FB1-4BF5-BB49-F22769DA3E2AQ29027136-88A4B9E1-FDBC-4426-97CE-E7BD25999AC0Q29248893-F4DA66AD-9FAA-4428-8472-B6F8104D7D09Q29547314-B33FB613-6CC3-4CF8-8191-26F6ED3E955AQ29614938-2C4AC794-38D2-40E0-95B2-038CC66BA1F3Q30365660-66A85CBC-95D3-4751-96DA-CD289D881667Q30395097-4DA722AA-27FC-432B-A905-CC16CC497390Q30399006-855B1C4E-730C-469A-BE90-57AD6AE207B9Q30442454-5479E9FF-EF45-4A00-9349-CC493A9E3684Q30455596-FD1E2DCB-D073-42CA-B34B-504AB80C3FBFQ30469815-DFB7FA29-2A6C-4186-8D1C-C45B4EF4E5F3Q30471456-A9C78E6B-0921-46BD-950B-CCD98AF5439FQ30490422-8BB121DB-0B51-4C44-9D1E-8076CD81E24DQ30528295-7190A92C-3364-4B10-841D-1601B4FB3191Q30542073-E7790CFF-26E7-432A-A1E2-6701A0E8C00C
P2860
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
@ast
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
@en
type
label
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
@ast
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
@en
prefLabel
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
@ast
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
@en
P2093
P356
P1476
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
@en
P2093
Dan G Duda
Jay S Loeffler
Jeffrey W Clark
Rakesh K Jain
P356
10.1038/NCPONC0403
P577
2006-01-01T00:00:00Z